• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Antibodies in Oncology Drug Pipeline Update 2014 Product Image

Antibodies in Oncology Drug Pipeline Update 2014

  • Published: July 2014
  • Region: Global
  • Bioseeker

The commercial and therapeutic success of antibodies like Rituxan, Avastin, and Erbitux will force the industry to look into the next generation of therapeutic antibodies, preparing themselves for the second wave in the lucrative field of therapeutic antibodies.
There are today 315 companies plus partners developing 701 antibody drugs in 1690 developmental projects in cancer. In addition, there are 8 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 342 drugs. Antibodies In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 316 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 308 out of the 310 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 56 classifications of molecular function and with pathway referrals to BioCarta, READ MORE >

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos